In view of the promising activity of the dual ETAR and ETBR antagonists in preclinical models of ovarian cancer, and the well-tolerated toxicity profile [53], [54], these molecules might be explored in CLL in combination with chemotherapy and kinase inhibitors. Here, EDNRB is linked to ovarian carcinoma.